Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States

Jérôme Eeckhoute

doi:10.3390/cells11162551

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States

Cells. 2022 Aug 17;11(16):2551. doi: 10.3390/cells11162551.

Author

Jérôme Eeckhoute¹

Affiliation

¹ U1011-EGID, Institut Pasteur de Lille, CHU Lille, Inserm, Univ. Lille, F-59000 Lille, France.

Abstract

Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease, has emerged as a major threat to public health [...].

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Liver Cirrhosis
Non-alcoholic Fatty Liver Disease*

Grants and funding

Work at Inserm U1011 is supported by the Agence Nationale de la Recherche (ANR) grants “HSCreg” (ANR-21-CE14-0032), “PreciNASH” (ANR-16-RHUS-0006-PreciNASH), and “European Genomic Institute for Diabetes” E.G.I.D (ANR-10-LABX-0046), a French State fund managed by ANR under the frame program Investissements d’Avenir I-SITE ULNE/ANR-16-IDEX-0004 ULNE and by Fondation Recherche Médicale (FRM grants EQU202203014645 and EQU202203014650).